Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States

被引:58
作者
Daly, Megan E. [1 ]
Perks, Julian R. [1 ]
Chen, Allen M. [1 ]
机构
[1] Univ Calif Davis, Ctr Comprehens Canc, Dept Radiat Oncol, Sacramento, CA 95817 USA
关键词
Lung cancer; Stereotactic body radiotherapy; Patterns-of-care; LUNG-CANCER; STAGE-I; PHASE-II; ABLATIVE RADIOTHERAPY; THERAPY; TUMORS; CARCINOMA; TOXICITY; OUTCOMES; SBRT;
D O I
10.1097/JTO.0b013e318279155f
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Radiation oncologists were surveyed to assess practice patterns in the use of stereotactic body radiotherapy (SBRT) for lung cancer. Methods: A customized patterns-of-care survey, consisting of 18 questions and two clinical scenarios, was e-mailed to 136 academic radiation oncologists and 768 community practitioners to evaluate the technical basis and delivery parameters associated with SBRT. Results: A total of 117 surveys were evaluable. The cited delivery techniques included: static noncoplanar beams (48%), intensity-modulated radiotherapy (41%), rotational intensity-modulated radiotherapy (47%), dynamic conformal arcs (7%), and small-beam delivery with fiducial tracking (24%), with 46% using multiple techniques. The immobilization methods included: stereotactic frame (10%), alpha cradle or vacuum-lock system (52%), wingboard (3%), stereotactic frame with an alpha cradle or vacuum-lock system (11%); combination of devices (14%), or no immobilization (9%). Abdominal compression was used by 51% and respiratory gating by 31%. For a peripheral T1N0 tumor, the preferred doses included: 25 to 34 Gy in one fraction (1%); 54 to 60 Gy in three fractions (56%), 48 to 50 Gy in four fractions (18%), and 50 to 60 Gy in five fractions (25%). For a centrally located T1N0 tumor, 58% recommended SBRT outside a clinical protocol, with recommended doses ranging from 40 to 60 Gy in three to 10 fractions. The recommended interval to first surveillance imaging ranged from 6 weeks or lesser (32%) to 25 weeks or more (2%). Conclusions: Considerable variation exists for thoracic SBRT with regard to dose selection, fractionation, immobilization, planning, management of central lesions, and surveillance. Ongoing prospective evaluation is recommended to identify best practices and provide continual process improvement.
引用
收藏
页码:202 / 207
页数:6
相关论文
共 25 条
[1]   Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy [J].
Baumann, Pia ;
Nyman, Jan ;
Hoyer, Morten ;
Wennberg, Berit ;
Gagliardi, Giovanna ;
Lax, Ingmar ;
Drugge, Ninni ;
Ekberg, Lars ;
Friesland, Signe ;
Johansson, Karl-Axel ;
Lund, Jo-Asmund ;
Morhed, Elisabeth ;
Nilsson, Kristina ;
Levin, Nina ;
Paludan, Merete ;
Sederholm, Christer ;
Traberg, Anders ;
Wittgren, Lena ;
Lewensohn, Rolf .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3290-3296
[2]   Stereotactic body radiation therapy: The report of AAPM Task Group 101 [J].
Benedict, Stanley H. ;
Yenice, Kamil M. ;
Followill, David ;
Galvin, James M. ;
Hinson, William ;
Kavanagh, Brian ;
Keall, Paul ;
Lovelock, Michael ;
Meeks, Sanford ;
Papiez, Lech ;
Purdie, Thomas ;
Sadagopan, Ramaswamy ;
Schell, Michael C. ;
Salter, Bill ;
Schlesinger, David J. ;
Shiu, Almon S. ;
Solberg, Timothy ;
Song, Danny Y. ;
Stieber, Volker ;
Timmerman, Robert ;
Tome, Wolfgang A. ;
Verellen, Dirk ;
Wang, Lu ;
Yin, Fang-Fang .
MEDICAL PHYSICS, 2010, 37 (08) :4078-4101
[3]   STEREOTAXIC HIGH-DOSE FRACTION RADIATION-THERAPY OF EXTRACRANIAL TUMORS USING AN ACCELERATOR - CLINICAL-EXPERIENCE OF THE FIRST 31 PATIENTS [J].
BLOMGREN, H ;
LAX, I ;
NASLUND, I ;
SVANSTROM, R .
ACTA ONCOLOGICA, 1995, 34 (06) :861-870
[4]   Residual 18F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control [J].
Bollineni, Vikram Rao ;
Widder, Joachim ;
Pruim, Jan ;
Langendijk, Johannes A. ;
Wiegman, Erwin M. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (04) :E551-E555
[5]   PROSPECTIVE, RISK-ADAPTED STRATEGY OF STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: RESULTS OF A PHASE II TRIAL [J].
Bral, Samuel ;
Gevaert, Thierry ;
Linthout, Nadine ;
Versmessen, Harijati ;
Collen, Christine ;
Engels, Benedikt ;
Verdries, Douwe ;
Everaert, Hendrik ;
Christian, Nicolas ;
De Ridder, Mark ;
Storme, Guy .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (05) :1343-1349
[6]   STEREOTACTIC BODY RADIATION THERAPY IN CENTRALLY AND SUPERIORLY LOCATED STAGE I OR ISOLATED RECURRENT NON-SMALL-CELL LUNG CANCER [J].
Chang, Joe Y. ;
Balter, Peter A. ;
Dong, Lei ;
Yang, Qiuan ;
Liao, Zhongxing ;
Jeter, Melenda ;
Bucci, M. Kara ;
McAleer, Mary F. ;
Mehran, Reza J. ;
Roth, Jack A. ;
Komaki, Ritsuko .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (04) :967-971
[7]   Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): Is FDG-PET a predictor of outcome? [J].
Clarke, Katy ;
Taremi, Mojgan ;
Dahele, Max ;
Freeman, Marc ;
Fung, Sharon ;
Franks, Kevin ;
Bezjak, Andrea ;
Brade, Anthony ;
Cho, John ;
Hope, Andrew ;
Sun, Alexander .
RADIOTHERAPY AND ONCOLOGY, 2012, 104 (01) :62-66
[8]  
Corradetti MN, 2012, NEW ENGL J MED, V366, P2327, DOI 10.1056/NEJMc1203770
[9]   Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer [J].
Haasbeek, Cornelis J. A. ;
Lagerwaard, Frank J. ;
Slotman, Ben J. ;
Senan, Suresh .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) :2036-2043
[10]   Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors [J].
Hara, R ;
Itami, J ;
Kondo, T ;
Aruga, T ;
Uno, T ;
Sasano, N ;
Ohnishi, K ;
Kiyozuka, M ;
Fuse, M ;
Ito, M ;
Naoi, K ;
Kohno, Y .
CANCER, 2006, 106 (06) :1347-1352